Scotiabank Initiates Coverage On Vera Therapeutics with Sector Outperform Rating, Announces Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on Vera Therapeutics with a Sector Outperform rating and set a price target of $60.
October 16, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scotiabank has initiated coverage on Vera Therapeutics with a Sector Outperform rating and a price target of $60, indicating a positive outlook.
The initiation of coverage with a Sector Outperform rating and a $60 price target by Scotiabank suggests a positive outlook for Vera Therapeutics. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100